SmallCap Sentinel: Innovative Stem Cell Company Follows the Road Less Controversial


IRVINE, Calif., Feb. 2, 2006 (PRIMEZONE) -- Amid a society split in public opinion as to the use of embryonic stem cells, one company looks to avert that controversial hurdle with a technology based on adult stem cells. Medistem Laboratories' (OTCBB:MDSM) portfolio of biotechnology looks to capitalize on the enormous human potential of stem cell research while shedding the ethical constraints of other stem cell research fields.

"This really opens a spate of ethical and hopefully technological doors for stem cell research," stated SmallCap Sentinel analyst, D.R. Clark. "Stem cell research is a burgeoning field of infinite possibilities but it has been hindered by a mixed bag of constraint and support based for the most part on embryonic stem cells. For Medistem, it's a non-issue as the company's science is from non-controversial sources."

The informational report "Looking at the Political Impact on Stem Cell Research" is available at www.SmallCapSentinel.com and will address issues affecting stem cell companies including Stemcells Inc. (Nasdaq:STEM), Aastrom Biosciences Inc. (Nasdaq:ASTM) and Geron Corp. (Nasdaq:GERN).

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The company creates these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities.

Individuals may also register to receive free future reports at: http://stockupticks.com/register.html

Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.

All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Trilogy Capital Partners for preparation and distribution of this report and other advertising services. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.



            

Contact Data